홈

Hydroxycamptothecin

Hydroxycamptothecin

규격

19685-09-7CAS 번호
613-598-9EC 번호
(19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dioneIUPAC 명칭
C20H16N2O5화학식
364.4 g/mol분자량
10-Hydroxycamptothecin; 19685-09-7; (S)-10-Hydroxycamptothecin; Hydroxycamptothecin; 10-hydroxycamptothecine; 10-HCPT; NSC-107124; 9Z01632KRV; (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo(11.8.0.02,11.04,9.015,20)henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; RefChem:77529; 613-598-9; (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 10-Hydroxy camptothecin; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; Hydroxycamptothecine; Camptothecin, hydroxy-; Camptothecine, 10-hydroxy-; 10-Hydroxy-Camptothecin; MFCD02093100; NSC107124; CHEMBL273862; Hydroxy camptothecine; (S)-4-ethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione; Camptothecin, 10-hydroxy-; (20S)-4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; NSC 107124; Hydroxycamptothecin-10; (S)-10-Hydroxycamptothecin hydrate; UNII-9Z01632KRV; CAMPTOTHECIN, 10-HYDROXY; (4S)-4,9-Dihydroxy-4-ethyl-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione ((S)-10-Hydroxycamptothecin); 10-Hydroxy-CPT; Spectrum_001639; (+)-(S)-10-HYDROXYCAMPTOTHECIN; 10-Hydroxycamp-totecin; SpecPlus_000763; Spectrum2_001660; Spectrum3_001621; Spectrum4_001815; Spectrum5_000549; ethyl(dihydroxy)[?]dione; SCHEMBL25875; BSPBio_003281; KBioGR_002454; KBioSS_002119; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4,9-dihydroxy-, hydrate, (S)-; DivK1c_006859; SPECTRUM1504123; SPBio_001819; orb1305050; SCHEMBL29350707; CHEBI:81395; HY-N0095R; KBio1_001803; KBio2_002119; KBio2_004687; KBio2_007255; KBio3_002501; Camptothecin 10-Hydroxy Impurity; DTXSID00941444; EX-A988; HY-N0095; (+)-10-HYDROXYCAMPTOTHECIN; BDBM50008922; CCG-38770; EBC-17074; MSK157282; s2423; s3898; AKOS015919293; AC-5502; CS-5193; DB12385; (S)-10-Hydroxycamptothecin (Standard); 10-HYDROXYCAMPTOTHECIN [WHO-DD]; NCGC00095986-01; NCGC00095986-02; NCGC00095986-03; NCGC00095986-04; NCGC00095986-07; NCGC00178165-01; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione-,4-ethyl-4,9-dihydroxy-, (S)-; AC-13221; AS-13196; NCI60_000173; SY010687; H1463; NS00018317; C17939; EN300-19810684; F787618; SR-05000002620; SR-05000002620-1; BRD-K63784565-001-02-1; BRD-K63784565-001-03-9; BRD-K63784565-001-05-4; BRD-K63784565-001-06-2; Q27155328; Z3093896188; Irinotecan EP Impurity B; Camptothecin 10-Hydroxy Impurity; 4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4-ETHYL-4,9-DIHYDROXY-, (4S)-; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione-,4-ethyl-4,9-dihydroxy-, (S)-; 4-Ethyl-4,10-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (10-hydroxycamptothecin)동의어